Emerging Markets Help Fresenius Kabi Offset US Pressures
As Firm Pushes Back Expectations For Biosimilars By A Year
Executive Summary
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
You may also be interested in...
Kabi Brings In Reddy’s Rituximab As Biosimilar Breakeven Date Retreats
The Fresenius group had much to say of Fresenius Kabi’s biosimilar business during the firm’s Q4 and year-end results call, which disclosed a US in-licensing deal for Dr Reddy’s proposed rituximab biosimilar and suggested additional biosimilar manufacturing is among its top priorities.
Medac Will Market Fresenius Kabi’s Adalimumab In Germany
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Fresenius Kabi Files EU Pegfilgrastim
Fresenius Kabi’s biosimilar pegfilgrastim rival to Neulasta has been accepted for review by the European Medicines Agency. The firm believes the “milestone” application will pave the way for a 2021 launch.